Valion Bio, Inc. $VBIO

What the company doesAI summary of filing

Tivic Health Systems, Inc. is a late-stage biopharmaceutical company focused on developing Entolimod, a recombinant TLR5 agonist, as a medical countermeasure for acute radiation syndrome and oncology-related conditions. The company is advancing Entolimod through regulatory approval toward potential government procurement for the Strategic National Stockpile, while also exploring expansion into indications such as neutropenia, thrombocytopenia, and radiation-induced mucositis. Tivic acquired worldwide exclusive license rights to Entolimod from Statera Biopharma in February 2025 and subsequently established Velocity Bioworks as a contract development and manufacturing organization subsidiary in December 2025. The company is pre-revenue and in clinical-stage development, with Entolimod in pre-BLA status under the FDA Animal Rule and Fast Track and Orphan Drug designations. [10-K 2026-03-30]

Segments: Entolimod (TLR5 agonist for acute radiation syndrome), Entolimod (for radiation-induced neutropenia and thrombocytopenia), Entolimod (for radiation-induced mucositis), Velocity Bioworks (contract development and manufacturing organization)